Clearmind Medicine Inc. (NASDAQ: CMND) announced that its drug candidate CMND-100 met the primary safety endpoint in a Phase I/IIa clinical trial for alcohol use disorder treatment.

The Vancouver-based biotech company reported results from the third cohort of the FDA-approved trial showed a high safety profile for CMND-100, even at higher dosages. The drug was well tolerated with no serious adverse events reported in the third cohort, according to the company's statement.

CMND-100 is described as a non-hallucinogenic, MEAI-based oral drug candidate. The Phase I/IIa trial is a multinational, multicenter study evaluating safety, tolerability, pharmacokinetics and preliminary efficacy in patients with moderate to severe alcohol use disorder.

The trial follows a dose-escalation design, with the third cohort receiving the highest dosage administered to date. Safety outcomes remained consistent with those observed in prior cohorts, the company said.

Clearmind focuses on developing what it terms second-generation psychedelic and neuroplastogen-derived therapeutics. The company holds an intellectual property portfolio of 19 patent families, including 31 granted patents.

The information is based on a company press release statement.